Press releases

Boston Scientific (NYSE: BSX) today announced that the Centers for Medicare & Medicaid Services (CMS) has approved its application for a transitional pass-through (TPT) payment category to...

Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation...

Boston Scientific Corporation (NYSE: BSX) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Jefferies 2020 Virtual Healthcare Conference on June 2. Joe Fitzgerald, executive vice president and president, Rhythm...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of concurrent offerings of 25,550,000 shares of its common stock ("Common Stock") at a price to the public of $34.25 per share and...

Boston Scientific Corporation (NYSE: BSX) announced that it has commenced concurrent offerings of $750.0 million of shares of its common stock ("Common Stock") and $750.0 million of shares of its...

Boston Scientific Corporation (NYSE: BSX) completed a public offering of $1.7 billion aggregate principal amount of its senior notes. The public offering consists of $500.0 million of 1.900% notes...

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of $1.7 billion aggregate principal amount of its senior notes under the company's shelf registration...

Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the next-generation WATCHMAN FLX™ Left Atrial...

Boston Scientific (NYSE: BSX) today announced the final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System presented at HRS 2020 SCIENCE, an...

Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming virtual investor conferences. On May 13, 2020, Dan Brennan, executive vice president and chief financial officer, and...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent on a reported basis, 3.2 percent on an...

Boston Scientific Corporation (NYSE: BSX) has signed a virtual power purchase agreement (VPPA) that represents the largest step the company has taken to achieve its goal of global carbon neutral...

Boston Scientific Corporation (NYSE: BSX) today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held exclusively in a virtual meeting format at the previously...

The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients. During this time of concern and disruption,...

Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences. On February 27, 2020, Susie Lisa, vice president, Investor Relations, will participate in a...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an...

Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents...

Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019, Susie Lisa, vice president, Investor Relations, and...

Boston Scientific Corporation (NYSE: BSX) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027 (the "Notes"). The Company has...

Boston Scientific Corporation (the "Company") (NYSE: BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...

Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...